Orchestra BioMed’s Q1 2026 update evidences ongoing enrollment in pivotal trials for two flagship therapies addressing hypertension and coronary artery disease. The company’s risk-sharing business model with leading device partners underpins its development and commercialization strategy. Near-term growth catalysts center on BACKBEAT trial completion mid-2026 and Virtue SAB enrollment through mid-2027. While financial resources remain sufficient for the short term, clinical outcomes and regulatory approvals present key uncertainties for future success.